Nasdaq panel grants nls pharmaceutics' request for extension to comply with continued listing requirements

Zurich, switzerland / accesswire / june 25, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a leading swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice from the nasdaq hearings panel ("panel") of the nasdaq stock market ("nasdaq") that it has granted the company an extension to regain compliance with the continued listing requirements for the nasdaq capital market, as discussed more fully below.
NLSP Ratings Summary
NLSP Quant Ranking